ADDITIONAL DETAILED ANALYSES FROM PHASE 2 STUDY 201 OF LECAN

/PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge,...

Related Keywords

Japan , Cambridge , Cambridgeshire , United Kingdom , China , Australia , Massachusetts , United States , New Zealand , Tokyo , Russia , Mike Hencke , Natacha Gassenbach , Christophera Viehbacher , Libby Holman , Haruo Naito , National Institute On , Linkedin , Communications Department , Twitter , Alzheimer Research , Alzheimer Network Trials Unit , Eisai Europe Ltd , Youtube , Ministry Of Health , Eisai Co Ltd , Prnewswire Eisai Co Ltd , European Medicines Agency , Advisory Committee , Investor Relations Department , Exchange Commission , Devices Agency , Facebook , Nasdaq , Biogen Inc , Public Relations Department , Eisai Inc , Washington University School Of Medicine , Drug Administration , National Medical Products Administration , Alzheimer Clinical Trial Consortium , United Nations Sustainable Development Goals Sdgs , Translational Research , National Institutes Of Health , Clinical Dementia Rating Sum Of Boxes , Scale Cognitive Subscale , Brand Name , Prescribing Information , Clinical Trials , New England Journal , Biologics License Application , Priority Review , Prescription Drug User Fee Act , Medical Devices Agency , Clinical Trial Consortium , National Institute , National Institutes , Tau Nexgen , Dominantly Inherited , Washington University School , Corporate Concept , United Nations Sustainable Development Goals , Private Securities Litigation Reform Act ,